Investors

CORPORATE OVERVIEW

BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods.

BenevolentAI has a consistently proven track-record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA.

BenevolentAI and Odyssey Acquisition announce business combination agreement

Investor contact

Julia Balanova
‍‍
Head of Investor Relations
investors@benevolent.ai

Resources

IMPORTANT

Access to the information and documents on this portion of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate. Please enter your country of residence:

Please enter your country of residence :

Important Information

DISCLAIMER – IMPORTANT

Due to applicable legal restrictions, the information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Canada, Japan or South Africa, or any other jurisdiction in which such release, publication or distribution would be unlawful. We apologise for any inconvenience this may cause.

Return to homepage →